- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-7771
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Emerging agents and regimens for polycythemia vera and essential thrombocythemia ; volume:9 ; number:1 ; day:28 ; month:5 ; year:2021 ; pages:1-7 ; date:12.2021
Biomarker Research ; 9, Heft 1 (28.5.2021), 1-7, 12.2021
- Creator
-
Shallis, Rory M.
Podoltsev, Nikolai A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40364-021-00298-5
- URN
-
urn:nbn:de:101:1-2021092419344843503602
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shallis, Rory M.
- Podoltsev, Nikolai A.
- SpringerLink (Online service)
Other Objects (12)
Polycythemia vera and essential thombocythemia - A single institution experience
Emerging agents and regimens for AML
Emerging agents and regimens for multiple myeloma
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Polycythemia Vera and Dengue Fever
New agents and regimens for diffuse large B cell lymphoma
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature
Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
Polycythemia vera and essential thombocythemia - A single institution experience
Emerging agents and regimens for AML
Emerging agents and regimens for multiple myeloma
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Polycythemia Vera and Dengue Fever
New agents and regimens for diffuse large B cell lymphoma
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature
Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
Polycythemia vera and essential thombocythemia - A single institution experience
Emerging agents and regimens for AML
Emerging agents and regimens for multiple myeloma
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Polycythemia Vera and Dengue Fever
New agents and regimens for diffuse large B cell lymphoma
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature
Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia